Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
Sponsor: Tanta University
Summary
NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-10-25
Completion Date
2027-07-20
Last Updated
2026-10-28
Healthy Volunteers
No
Conditions
Interventions
Placebo
Placebo drug will have the same look and taste of the other treatment
Rupatadin
Rupatadine (RUP), an H1 receptor antagonist, also inhibits the actions of platelet activation factor (PAF) and is particularly useful in allergic rhinitis and urticaria
Locations (1)
Faculty of Medicine, Tanta University, Tanta, Egypt
Tanta, New Damietta, Egypt